Small molecule · developed by Pulmatrix
PUR1800 is a drug product of RV1162 in bulk powder pre-metered into HPMC capsules for oral inhalation by a passive dry powder inhaler. It is studied in chronic obstructive pulmonary disease (COPD).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04759807 | Phase 1 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | PULM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Obstructive Pulmonary Disease (COPD)
Updated Oct 25, 2026. Something wrong or missing? Report it on the PULM page.
See PULM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PULM catalysts and pipeline →